Serpinf2-Binding Molecules and Method of Use Thereof
AssigneeTranslational Sciences Inc.
InventorGuy L. Reed
Life of this patent
Estimating the term…
Abstract
Compositions and methods of using SerpinF2-binding molecules for preventing and/or reducing organ damage, functional disability or mortality in a patient at risk due to the activity of SerpinF2 and/or plasminogen activators on tissue injury. Also provided are compositions and methods of using SerpinF2-binding molecules for inhibiting hemorrhage, edema, and apoptosis. Methods for the preparation of medicaments for such methods of treatment and prevention are provided.
Claims29
1-28. (canceled)
A method of treating or preventing hemorrhage or edema in a patient in need thereof, comprising administering to the patient an effective amount of an anti-SerpinF2 antibody or fragment thereof that reduces SerpinF2 activity or concentration, wherein the hemorrhage or edema is cardiac, hepatic, pancreatic, respiratory or renal.
A method of inhibiting disability or death from endogenous or pharmacologic tissue plasminogen activator (TPA) mediated hemorrhage or edema in a patient in need thereof, the method comprising administering to the patient an effective amount of an anti-SerpinF2 antibody or fragment thereof that reduces SerpinF2 activity or concentration, wherein the hemorrhage or edema is cardiac, hepatic, pancreatic, respiratory or renal.
A method of inhibiting edema or tissue plasminogen activator (TPA) toxicity in a lung of a patient in need thereof comprising administering to said patient an effective amount of an anti-SerpinF2 antibody or fragment thereof that reduces SerpinF2 concentration or activity in said patient to inhibit the organ edema or tissue plasminogen activator (TPA) toxicity.
A method of treating or preventing morbidity or disability, or preventing death, from cellular damage, hemorrhage, or organ swelling after tissue injury, due to SerpinF2 activity, in a patient in need thereof, the method comprising administering to the patient an effective amount of an anti-SerpinF2 antibody or fragment thereof that reduces SerpinF2 activity or concentration, wherein the cellular damage, hemorrhage, or organ swelling is cardiac, hepatic, pancreatic, respiratory or renal.
Dependencies are inferred from the claim text.